Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

2.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

3.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

4.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

5.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

6.

Improvement of the cardiac marker N-terminal-pro brain natriuretic peptide through adjustment for renal function: a stratified multicenter trial.

Luchner A, Weidemann A, Willenbrock R, Philipp S, Heinicke N, Rambausek M, Mehdorn U, Frankenberger B, Heid IM, Eckardt KU, Holmer SR.

Clin Chem Lab Med. 2010;48(1):121-8. doi: 10.1515/CCLM.2010.011.

PMID:
20047532
7.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

8.

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

Orth SR, Stöckmann A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schäfer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P.

Kidney Int. 1998 Sep;54(3):926-31.

9.

The BsmI vitamin D-receptor polymorphism and secondary hyperparathyroidism.

Schmidt S, Chudek J, Karkoszka H, Heemann U, Reichel H, Rambausek M, Kokot F, Ritz E.

Nephrol Dial Transplant. 1997 Aug;12(8):1771-2. No abstract available.

PMID:
9269677
10.

Anaphylactoid reactions during dextran apheresis may occur even in the absence of ACE-inhibitor administration.

Schwarzbeck A, Hilgenfeldt U, Riester U, Rambausek M, Kiral A.

Nephrol Dial Transplant. 1997 May;12(5):1083-4. No abstract available.

PMID:
9175084
11.

Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.

MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E.

Nephrol Dial Transplant. 1996 Dec;11(12):2449-52.

PMID:
9017621
12.

More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension.

Geberth S, Stier E, Zeier M, Mayer G, Rambausek M, Ritz E.

J Am Soc Nephrol. 1995 Dec;6(6):1643-8.

13.

Abdominal emergency in a dialysis patient: haemolysis from kinking of dialysis tubing.

Rambausek M, Wallmeier K, Schwarzbeck A, Ritz E.

Nephrol Dial Transplant. 1995 Nov;10(11):2141-3. No abstract available.

PMID:
8643187
14.

The role of the parathyroid glands in the uremic syndrome.

Ritz E, Stefanski A, Rambausek M.

Am J Kidney Dis. 1995 Nov;26(5):808-13. Review.

PMID:
7485137
15.

Metformin-associated lactic acidosis in diabetic patients with acute renal failure.

Schwarzbeck A, Hastka J, Kühnle F, Rambausek M.

Nephrol Dial Transplant. 1995;10(3):425-6. No abstract available.

PMID:
7792050
16.

Non-occlusive mesenteric infarction in dialysis patients: the importance of prevention and early intervention.

Zeier M, Wiesel M, Rambausek M, Ritz E.

Nephrol Dial Transplant. 1995;10(6):771-3. No abstract available.

PMID:
7566602
17.

[Nonocclusive intestinal ischemia as a complication of hemodialysis treatment].

Zeier M, Hupp T, Wiesel M, Rambausek M, Ritz E.

Dtsch Med Wochenschr. 1993 Jul 16;118(27-28):1020-4. German.

PMID:
8334949
18.

[Dietary aspects and nutritional guidelines in kidney diseases].

Rambausek M, Zeier M, Ritz E.

Z Arztl Fortbild (Jena). 1993 Apr 12;87(4):315-22. Review. German. No abstract available.

PMID:
8511943
19.

[beta-Sympathomimetics against hyperkalemia in kidney failure].

Rambausek M, Kluge R.

Dtsch Med Wochenschr. 1993 Jan 29;118(4):120-1. German. No abstract available.

PMID:
8428555
20.

Structural causes of cardiac dysfunction in uremia.

Rambausek M, Amann K, Mall G, Ritz E.

Ren Fail. 1993;15(3):421-8. Review.

PMID:
8516501

Supplemental Content

Loading ...
Support Center